Cingulate Inc. Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Cingulate Inc. reported a Q3 net loss of $7.3 million due to increased R&D and administrative costs. Key developments include FDA acceptance of NDA for CTx-1301, $6 million financing, and Bryan Downey's appointment as Chief Commercial Officer. The company secured a $4.3 million PDUFA fee waiver and a supply agreement with Bend Bio Sciences. Positive Phase 3 results for CTx-1301 were presented, with a potential 2026 launch. Additional capital is needed for commercialization efforts.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments